@article {Tekes:2013:0929-8673:3300,
title = "Medicinal Chemistry of Antimigraine Drugs",
journal = "Current Medicinal Chemistry",
parent_itemid = "infobike://ben/cmc",
publishercode ="ben",
year = "2013",
volume = "20",
number = "26",
publication date ="2013-09-01T00:00:00",
pages = "3300-3316",
itemtype = "ARTICLE",
issn = "0929-8673",
url = "https://www.ingentaconnect.com/content/ben/cmc/2013/00000020/00000026/art00012",
keyword = "Migraine treatment, pharmacokinetics, pharmacodynamics",
author = "Tekes, K. and Szegi, P. and Hashemi, F. and Laufer, R. and Kalasz, H. and Siddiq, A. and Ertsey, C.",
abstract = "Migraine is one of the most frequent neurological disorder with high impact on the quality of life. Primary headaches such as migraine are pathophysiologically complex disorders. The concept of the trigeminovascular system dysfunction in migraine has led to a number of drug discoveries
dramatically changing the treatment options. Acute and prophylactic therapy targeting either the trigeminovascular system or central structures involve several groups of drugs with peculiar medicinal chemistry. In the proposed review up to date concept of treatment strategy, medicinal chemistry
data of the drugs used will be summarized. The present review gives detailed information on drugs effective in aborting migraine attacks (by inhibiting prostanoid synthesis, are agonists of serotonin 5-HT1B/D receptors, on the recently introduced CGRP-receptor antagonists) and the drugs recommended
for prophylactic treatment (selected beta-adrenergic receptor antagonists, Ca-channel inhibitors, antiepileptics, antidepressants). The pharmacokinetics, fate in the body (absorption, distribution, metabolism, excretion) and significant pharmacological effects as well as the recent bioanalytical
methods for their determination are presented.",
}